Seattle Genetics Highlights Data From SGN-CD19A Antibody-Drug Conjugate Program

(RTTNews) - Seattle Genetics, Inc. (SGEN) highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL), presented at the 57th American Society of Hematology.

The updated data from Phase 1 Clinical Trials support further clinical evaluation of SGN-CD19A in Randomized Phase 2 Trials: Testing Novel Regimens for Frontline and Relapsed DLBCL.

Preclinical data from a novel antibody-drug conjugate (ADC) program called SGN-CD19B in B-cell malignancies will also be featured in an oral presentation.

These two ADCs, 19A and SGN-CD19B, both target CD19 and utilize two of Seattle Genetics' proprietary payloads, monomethyl auristatin F (MMAF) and a pyrrolobenzodiazepine (PBD) dimer, respectively. The company has initiated the first of two planned phase 2 trials of 19A in DLBCL and plans to advance SGN-CD19B into a phase 1 trial in 2016.